Overview of a Phase I study of ONO/GS-4059 in relapsed and refractory mature B-cell malignancies - European Medical Journal

Continue

Overview of a Phase I study of ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Oncology

Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in relapsed and refractory mature B-cell malignancies. Prof. Dyer presents the data showing the reduced toxicity of ONO/GS-4059 in comparison with the 1st generation BTK inhibitor ibrutinib.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given